These mRNA vaccines elicit antibodies against the viral spike (S) protein that block S protein receptor-binding domain (RBD) interactions with the angiotensin-converting enzyme 2 (ACE2) receptor or prevent the S protein from mediating viral-host membrane fusion, thus stopping host cell infection (10, 11). The gene discussed is PROS1; the disease is infection.